Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cancer Vaccines
Peter J. DeMaria, Marijo Bilušić
Hematology/Oncology Clinics of North America (2019) Vol. 33, Iss. 2, pp. 199-214
Closed Access | Times Cited: 113

Showing 1-25 of 113 citing articles:

Cancer vaccines: the next immunotherapy frontier
Matthew J. Lin, Judit Svensson‐Arvelund, Gabrielle S. Lubitz, et al.
Nature Cancer (2022) Vol. 3, Iss. 8, pp. 911-926
Closed Access | Times Cited: 581
Colorectal Cancer Immunotherapy: Options and Strategies
Nor Adzimah Johdi, Nur Fazilah Sukor
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 348
Vaccine Therapies for Cancer: Then and Now
Michael A. Morse, William R. Gwin, Duane A. Mitchell
Targeted Oncology (2021) Vol. 16, Iss. 2, pp. 121-152
Open Access | Times Cited: 173
Exosome-Based Vaccines: History, Current State, and Clinical Trials
Patrick Santos, Fausto Almeida
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 158
Immunotherapy for glioblastoma: the promise of combination strategies
Mathilde Bausart, Véronique Préat, Alessio Malfanti
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 144
Drug repurposing for cancer therapy
Ying Xia, Ming Sun, Hai Huang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 107
Development of Peptide-Based Vaccines for Cancer
Noraini Abd-Aziz, Chit Laa Poh
Journal of Oncology (2022) Vol. 2022, pp. 1-17
Open Access | Times Cited: 93
Assessing the Future of Solid Tumor Immunotherapy
Prajna Guha, Kara R. Heatherton, Kyle O’Connell, et al.
Biomedicines (2022) Vol. 10, Iss. 3, pp. 655-655
Open Access | Times Cited: 72
Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies
Neha R. Raghani, Mehul R. Chorawala, Mayuresh Mahadik, et al.
Medical Oncology (2024) Vol. 41, Iss. 2
Closed Access | Times Cited: 25
Leveraging mRNA technology for antigen based immuno-oncology therapies
Charalampos S. Floudas, Siranush Sarkizova, Michele Ceccarelli, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010569-e010569
Open Access | Times Cited: 4
Trial watch: dendritic cell vaccination for cancer immunotherapy
Jenny Sprooten, Jolien Ceusters, An Coosemans, et al.
OncoImmunology (2019) Vol. 8, Iss. 11, pp. 1638212-1638212
Open Access | Times Cited: 134
Tumor cell membrane enveloped aluminum phosphate nanoparticles for enhanced cancer vaccination
Jingyao Gan, Guangsheng Du, Chun‐Ting He, et al.
Journal of Controlled Release (2020) Vol. 326, pp. 297-309
Closed Access | Times Cited: 95
Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine
Jingyi Xia, Yang‐Bao Miao, Xi Wang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 152, pp. 113250-113250
Open Access | Times Cited: 49
Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines
Anna Hargrave, Abu Salim Mustafa, Asma Hanif, et al.
Vaccines (2023) Vol. 11, Iss. 11, pp. 1633-1633
Open Access | Times Cited: 23
Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments
Lisa Feldman
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 11
Cancer vaccines: current status and future directions
Yi Zhou, Yuquan Wei, Xiaohe Tian, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 1
Mussel‐Inspired Polydopamine: The Bridge for Targeting Drug Delivery System and Synergistic Cancer Treatment
Wenyan Wang, Zhuo Tang, Yi Zhang, et al.
Macromolecular Bioscience (2020) Vol. 20, Iss. 10
Closed Access | Times Cited: 67
Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis
Volker Schirrmacher
Biomedicines (2020) Vol. 8, Iss. 3, pp. 61-61
Open Access | Times Cited: 54
Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine
Hua Zhong, Shuai Liu, Fang Cao, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 47
Advances in Delivery of Chemotherapeutic Agents for Cancer Treatment
Asmita Yadav, Sakshi Singh, Harmik Sohi, et al.
AAPS PharmSciTech (2021) Vol. 23, Iss. 1
Closed Access | Times Cited: 44
Immunotherapy
Manisha Sahu, Hemakumari Suryawanshi
Journal of Oral and Maxillofacial Pathology (2021) Vol. 25, Iss. 2, pp. 371-371
Open Access | Times Cited: 41
Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines
Mariam Oladejo, Wyatt Paulishak, Laurence M. Wood
Seminars in Cancer Biology (2022) Vol. 88, pp. 81-95
Open Access | Times Cited: 35
Nanotechnology for next-generation cancer immunotherapy: State of the art and future perspectives
Yunching Chen
Journal of Controlled Release (2023) Vol. 356, pp. 14-25
Closed Access | Times Cited: 21
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
Francesca Ruzzi, Maria Sofia Semprini, Laura Scalambra, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12963-12963
Open Access | Times Cited: 21
In Silico Studies to Support Vaccine Development
Leonor Saldanha, Ülo Langel, Nuno Vale
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 654-654
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top